PROK Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
174.0K
+16.0%
150.0K
-33.6%
226.0K
+0.4%
225.0K
+3.7%
217.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
174.0K
+16.0%
150.0K
-33.6%
226.0K
+0.4%
225.0K
+3.7%
217.0K
Operating Expenses
53.9M
+11.1%
48.5M
+7.4%
45.2M
-1.0%
45.6M
+17.6%
38.8M
R&D
40.8M
+13.2%
36.1M
+6.7%
33.8M
-0.9%
34.2M
+27.4%
26.8M
SG&A
13.1M
+5.3%
12.4M
+9.8%
11.3M
-1.1%
11.4M
-4.2%
11.9M
Operating Income
-53758000
-11.1%
-48373000
-7.7%
-44933000
+1.0%
-45371000
-17.7%
-38539000
EBITDA
-52085000
-11.5%
-46695000
-7.9%
-43275000
+0.6%
-43534000
-18.1%
-36866000
Net Income
-51793000
-11.5%
-46436000
-9.0%
-42621000
-4.3%
-40852000
-14.0%
-35843000
EPS (Basic)
$-0.17
-13.3%
$-0.15
-7.1%
$-0.14
-7.7%
$-0.13
-8.3%
$-0.12
EPS (Diluted)
$-0.17
-13.3%
$-0.15
-7.1%
$-0.14
-7.7%
$-0.13
-8.3%
$-0.12
Shares (Diluted)
207.8M
+11.4%
186.6M
+31.5%
141.9M
-0.8%
143.1M
+6.0%
135.0M
ProKidney (PROK) — Financials